This could well describe the pharmaceutical giant AstraZeneca when it halted its coronavirus vaccine’s global trials because some of the volunteers experienced mysterious illnesses.
In a statement, the company said, “as part of the ongoing randomized, controlled global trials of the Oxford coronavirus vaccine, our standard review process triggered a pause to vaccination to allow the review of safety data.
Though the Data and Safety Monitoring Board (DSMB) usually monitors trials for adverse events and can order a pause or halt a prosecution, AstraZeneca did not say who had stopped the trial.
Known as the Oxford Vaccine, the drug company is currently partnered with Britain’s University of Oxford, and in the United States and the UK, Latin America, Asia, Europe, and Africa.
Explaining some possible causes to this “in large trials, illnesses will happen by chance but must be independently reviewed to check this carefully. We are working to expedite the review of the single event to minimize any potential impact on the trial timeline. We are committed to the safety of our participants and the highest standards of conduct in our trials.”
Moreover, “We, the undersigned biopharmaceutical companies, want to make clear our ongoing commitment to developing and testing potential vaccines for COVID-19 in accordance with high ethical standards and sound scientific principles,” the statement read.
The following companies’ chief executives have signed the standard principles: AstraZeneca, BioNTech GlaxoSmithKline, Johnson & Johnson, Merck, Moderna, Novavax, Pfizer, and Sanofi.
This week, AstraZeneca joined eight other companies in signing a pledge promising to secure the government’s approval for any sudden movement in the vaccine versus coronavirus vaccine. This also made them commit that unless safe for injection, they will not release. Data and results are a crucial factor to be observed.
“We believe this pledge will help ensure public confidence in the rigorous scientific and regulatory process by which COVID-19 vaccines are evaluated and may ultimately be approved,” they added.
Companies are working with the right body deadline or experts with drugs like the US Food and Drug Administration with these sensitives. They are required to give either emergency use authorization or full approval to any vaccine before distribution massively.
In time of the US Election in November, US President Donald Trump said he could approve at least one of the three.
Despite many groups saying they cannot reach the timeline, only Biotech CEO and co-founder Ugur Sahin believes the vaccine he is developing with Pfizer could be ready for regulatory approval by mid-October.
Meanwhile, the director of the National Institute of Allergy and Infectious Diseases, Dr. Tony Fauci, added that it’s technically possible that if a DSMB saw strong proof a vaccine was working before a trial was completed, it could issue to stop the prosecution so more people could get the vaccine, but within December.
Caif, who was also a commissioner for two years, included “One of the things that have had me on pins and needles the last four years is literally Trump could do this with any drug or device or vaccine anytime he wants to,” said Califf, who was commissioner from January 2016 through January 2018.